A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
NCT07226427
·
clinicaltrials.gov ↗
PHASE1
Phase
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Platinum-resistant Ovarian Cancer
Interventions
DRUG:
MEN2501
Sponsor
Stemline Therapeutics, Inc.